文献速递神经肿瘤

BRD4作为无功能性和生长激素型垂体腺瘤的治疗靶点

BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.
PubMed 文献 · Neuro Oncol · 2020-01-01

本研究检测BRD4在无功能性垂体腺瘤(NFPA)、生长激素型垂体腺瘤(GHPA)及正常垂体组织中的表达,并在GH3、MMQ细胞系、患者来源肿瘤细胞及小鼠异种移植模型中评估BRD4抑制剂ZBC-260的疗效。结果显示BRD4在NFPA和GHPA中过表达,ZBC-260可显著抑制垂体腺瘤细胞增殖并下调c-Myc、Bcl2及相关基因表达,提示BRD4是NFPA和GHPA有前景的治疗靶点。

要点

  • BRD4在无功能性垂体腺瘤和生长激素型垂体腺瘤中过表达。
  • BRD4抑制剂ZBC-260在体外和体内均显著抑制垂体腺瘤细胞增殖。
  • ZBC-260可下调c-Myc、Bcl2及相关基因表达。

核心结论

  • BRD4在NFPA和GHPA中过表达。
  • BRD4抑制剂ZBC-260在体外和体内均显著抑制垂体腺瘤细胞增殖。
  • 作者认为BRD4是NFPA和GHPA有前景的治疗靶点。

研究设计与样本

  • 检测BRD4在NFPA、GHPA和正常垂体组织中的表达。
  • 在GH3和MMQ细胞系、患者来源肿瘤细胞及垂体腺瘤小鼠异种移植模型中评估BRD4抑制剂的疗效。
  • 采用标准蛋白质印迹、实时PCR和流式细胞术检测BRD4抑制剂对细胞周期进展、凋亡及下游基因表达模式的影响。

主要发现

  • 免疫组化研究显示BRD4在NFPA和GHPA中过表达。
  • 体外和体内研究显示BRD4抑制剂ZBC-260显著抑制垂体腺瘤细胞增殖。
  • 机制研究显示ZBC-260可下调c-Myc、B细胞淋巴瘤2(Bcl2)及相关基因表达,这些是垂体肿瘤发生的关键因子。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonfunctioning pituitary adenoma (NFPA) and growth hormone pituitary adenoma (GHPA) are major subtypes of pituitary adenomas (PAs). The primary treatment is surgical resection. However, radical excision remains challenging, and few effective medical therapies are available. It is urgent to find novel targets for the treatment. Bromodomain-containing protein 4 (BRD4) is an epigenetic regulator that leads to aberrant transcriptional activation of oncogenes. Herein, we investigated the pathological role of BRD4 and evaluated the effectiveness of BRD4 inhibitors in the treatment of NFPA and GHPA. METHODS: The expression of BRD4 was detected in NFPA, GHPA, and normal pituitary tissues. The efficacies of BRD4 inhibitors were evaluated in GH3 and MMQ cell lines, patient-derived tumor cells, and in vivo mouse xenograft models of PA. Standard western blots, real-time PCR, and flow cytometry experiments were performed to investigate the effect of BRD4 inhibitors on cell cycle progression, apoptosis, and the expression patterns of downstream genes. RESULTS: Immunohistochemistry studies demonstrated the overexpression of BRD4 in NFPA and GHPA. In vitro and in vivo studies showed that treatment with the BRD4 inhibitor ZBC-260 significantly inhibited the proliferation of PA cells. Further mechanistic studies revealed that ZBC-260 could downregulate the expression of c-Myc, B-cell lymphoma 2 (Bcl2), and related genes, which are vital factors in pituitary tumorigenesis. CONCLUSION: In this study, we determined the overexpression of BRD4 in NFPA and GHPA and assessed the effects of BRD4 inhibitors on PA cells in vitro and in vivo. Our findings suggest that BRD4 is a promising therapeutic target for NFPA and GHPA.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Shi C, Ye Z, Han J, et al. BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma. Neuro Oncol. 2020. PMID: 32246150. doi:10.1093/neuonc/noaa084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。